Please ensure Javascript is enabled for purposes of website accessibility

Here's Why iRhythm Technologies Stock Is Making Big Gains Today

By Cory Renauer – Sep 13, 2021 at 12:58PM

Key Points

  • Investors are cheering the appointment of DexCom's former chief operating officer to the lead role at iRhythm Technologies.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new CEO with an impressive record is giving investors hope for a rapid turnaround for the heart monitor maker.

What happened

Shares of iRhythm Technologies (IRTC 1.20%), a company that makes wearable heart monitors, are posting big gains today. Investors fired up about the appointment of Quentin Blackford as CEO pushed the stock 33.8% higher as of 12:25 p.m. EDT on Monday.

So what 

The stock crashed earlier this year when the company failed to secure a favorable reimbursement rate from Medicare for the Zio XT, its heart arrhythmia detection device for high-risk patients. Despite the setback, the company expects total revenue to rise about 22% year over year to $323 million in 2021.

Blackford previously served as the chief operating officer of DexCom, a highly successful manufacturer of wearable blood glucose monitors that had reimbursement issues of its own. DexCom's operations turned strongly profitable last year, and it looks as if investors expect him to do the same for iRhythm in the years ahead. 

Three investors looking at stocks.

Image source: Getty Images.

Now what

Sales of iRhythm's devices are growing, but they would grow a lot faster with a national pricing determination from the Centers for Medicare and Medicaid Services. It's hoped that Blackford can make more progress on this front than his predecessor once he officially takes the helm on Oct. 4.

Before a Medicare contractor slashed the reimbursement price for the Zio XT, iRhythm's market cap had risen past $7 billion. This company is still the only manufacturer of simple, wearable solutions for detecting life-threatening heart arrhythmias. It's probably just a matter of time before the stock reaches a new peak.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

iRhythm Technologies, Inc. Common Stock Stock Quote
iRhythm Technologies, Inc. Common Stock
$106.79 (1.20%) $1.27
DexCom Stock Quote
$114.04 (1.82%) $2.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.